Compare SBUX & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBUX | SNY |
|---|---|---|
| Founded | 1971 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.1B | 104.5B |
| IPO Year | 1994 | 2001 |
| Metric | SBUX | SNY |
|---|---|---|
| Price | $100.59 | $42.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 5 |
| Target Price | ★ $104.39 | $58.00 |
| AVG Volume (30 Days) | ★ 5.1M | 2.1M |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | 2.35% | ★ 3.47% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.62 | N/A |
| Revenue | ★ $37,184,400,000.00 | N/A |
| Revenue This Year | $4.88 | $3.49 |
| Revenue Next Year | $5.15 | $6.10 |
| P/E Ratio | $62.90 | ★ $6.14 |
| Revenue Growth | ★ 2.79 | N/A |
| 52 Week Low | $77.99 | $40.89 |
| 52 Week High | $110.51 | $52.68 |
| Indicator | SBUX | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 37.05 |
| Support Level | $93.59 | $42.30 |
| Resistance Level | $101.18 | $45.22 |
| Average True Range (ATR) | 2.27 | 0.61 |
| MACD | -0.72 | -0.27 |
| Stochastic Oscillator | 11.60 | 0.62 |
Starbucks stands out as the world's biggest and most recognizable coffee brand, powered by ultracustomizable beverages in-store and a sweeping footprint of nearly 41,000 cafes in over 80 countries. About 52% are company-operated, with the balance run by licensees. The company operates roasteries and sells across its North America (74% of revenue as of the end of fiscal 2025), international (21%), and channel development (5%) segments. The brand collects revenue from company-operated stores, licensee royalties, equipment and product sales, retail ready-to-drink beverages, and packaged coffee.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.